IMMUNOLOGY AND IMMUNOTHERAPY

描述：（申请人描述）该计划的总体目标， 免疫学和免疫治疗是了解免疫的基本要素 以及癌细胞逃避免疫系统的机制， 可以制定干预策略以减少癌症负担。这是 通过促进合作和鼓励 广泛调查免疫与 癌科罗拉多大学癌症中心领导层重组了 1998年和1999年对癌症中心的结构进行了改革，以便更好地促进 转化研究和合作，并加强对癌症的关注。 来自成人临床肿瘤学的旧黑色素瘤和神经肿瘤学焦点小组 与免疫学计划相结合，形成了新的免疫学， 免疫治疗计划。因此，免疫学计划和 免疫疗法现在有35名正式成员持有主要任命， 细胞和结构生物学系，皮肤科，免疫学，医学， 神经科、病理科、儿科、放射科、放射肿瘤科和外科。 该小组包括免疫学系主任和三名成员 国家科学院院长计划成员有近1200万美元 每年的直接费用来自90多个赠款。自上次审查以来， 所有机构，特别是国家癌症研究所， 和NIH。项目成员贡献了250份出版物，约40 涉及与两个或更多癌症中心成员合作的百分比， 自行骨髓移植、黑色素瘤、 治疗，并控制细胞死亡和分化。 招聘对人类肿瘤免疫学感兴趣的新教师， 免疫治疗已经开始。癌症中心提供种子资金， 支持试点项目，这些项目可能会发展成为一个计划项目应用程序。 乳腺癌、脑癌和皮肤癌免疫疗法的临床试验正在进行中， 并且已经进行了关于肺癌治疗的有希望的临床前研究。

Description: (Applicant's Description) The overall goal of the Program in Immunology and Immunotherapy is to understand the basic elements of immunity and the mechanisms by which cancer cells evade the immune system so that new intervention strategies can be developed to reduce the cancer burden. This is accomplished programmatically by fostering collaborations and encouraging a broad range of investigations into the connections between immunity and cancer. The University of Colorado Cancer Center leadership reorganized the structure of the Cancer Center in 1998 and 1999 in order to better promote translational research and collaborations, and to strengthen the cancer focus. The old Melanoma and Neuro-oncology focus groups from Adult Clinical Oncology were combined with the Immunology Program to form the new Immunology and Immunotherapy Program. As a consequence, the Program in Immunology and Immunotherapy now has 35 full members holding primary appointments in the Departments of Cell and Structural Biology, Dermatology, Immunology, Medicine, Neurology, Pathology, Pediatrics, Radiology, Radiation Oncology, and Surgery. The group includes the Chair of the Department of Immunology and three members of the National Academy of Sciences. Program members have nearly $12 million in annual direct costs from more than ninety grants. Since the last review, there has been an increase in grants from all agencies, especially the NCI, and NIH. Program members contributed 250 publications, approximately 40 percent involving collaborations with two or more Cancer Center members as authors. Program project initiatives in bone marrow transplantation, melanoma therapy, and control of cell death and differentiation were undertaken. Recruitment of new faculty with interests in human tumor immunology and immunotherapy has been initiated. The Cancer Center provided seed funding to support pilot projects that might evolve into a program project application. Clinical trials in breast, brain, and skin cancer immunotherapy are underway, and promising pre-clinical studies on lung cancer treatment have been made.